Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-07-03
2007-07-03
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C435S456000, C514S04400A
Reexamination Certificate
active
10191760
ABSTRACT:
The invention relates to adenoviral vectors. More particularly, this invention relates to recombinant high capacity adenoviral vectors which can be employed in the treatment of hemophilia A, as well as methods and process for their creation and use.
REFERENCES:
patent: WO 97/45550 (1997-12-01), None
Connelly et al., “Complete short-term correction of canine hemophilia A by in vivo gene therapy,” Blood 88 (10): 3846-3853, 1996.
Reddy et al., “Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector,” Mol. Ther. 5 (1): 63-73, Jan. 2002.
Gallo-Penn et al., “Systemic delivery of an adenoviral vecotr encoding canine factor VIII results in short-term phenotypic correction, inhibitor development and biphasic liver toxicity in hemophilia A dogs,” Blood 97 (1): 107-113, Jan. 1, 2001.
Balague et al., “Sustained high-level expression of full-length human factor VIII and resoration of clotting activity in hemophiliac mice using a minimal adenovirus vector,” Blood 95: 820-828, 2000.
Brown et al., “Helper-dependent adenovirus delivery of a canine FVIII B-domain deleted transgene in murine and canine models of hemophilia A,” Blood 98 (11, pt. 1): 695a-696a, Nov. 16, 2001.
VandenDriessche et al., “Viral vector-mediated gene therapy for hemophilia,” Curr. Gene Ther. 1 (3): 301-315, Sep. 2001.
Brown et al., “Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model for sever hemophilia A,” Blood 103 (3): 804-810, Feb. 1, 2004.
Chuah et al., Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors, Blood, Mar. 1, 2003, pp. 1734-1743, vol. 101, No. 5.
Linthout et al., Effect of Promoters and Enhancers on Expression, Transgene DNA Persistence, Hepatotoxicity After Adenoviral Gene Transfer the Human Apolipoprotein A-I, Human Gene Therapy, May 1, 2002, pp. 829-840, vol. 13.
VandenDricsche et al., Gene therapy for hemophilia A using onco-retroviral, lentiviral and gutless adenoviral vectors, Abstract, 9th Meeting of the European Society of Gene Therapy, Nov. 2-4, 2001, Antalya, Turkey, cover page, p. 3 and p. 26.
Presentation, Adenoviral Vectors, presented Nov. 2, 2001.
Brown et al., Helper-dependent adenovirus delivery of a canine FVIII B-domain deleted transgene in murine and canine models of hemophilia A, Abstract, Blood, Nov. 16, 2001, pp. 695a-696a, vol. 98, No. 11.
Brown et al., Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A, Blood, Feb. 1, 2004, pp. 804-810, vol. 103, No. 3.
Chuah et al., Biosafety of Adenoviral Vectors, Current Gene Therapy, 2003, pp. 1-7, vol. 3, No. 6.
High et al., Immune Response to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B, Molecular Therapy, May 2004, pp. S383-S384, vol. 9, Supplement 1.
Raper et al., Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Abstract, Molecular Genetics and Metabolism, Sep.-Oct. 2003, pp. 148-158, vol. 80.
Chuah Marinee
Kochanek Stefan
Schiedner Gudrun
Vandendriessche Thierry
Priebe Scott D.
TraskBritt
Vlaams Interuniversitair Instituut voor Biotechnologie VZW
LandOfFree
High capacity recombinant adenoviral vector for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High capacity recombinant adenoviral vector for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High capacity recombinant adenoviral vector for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3753039